8-KRegulation FD

Elevance Health, Inc. 8-K Report, Regulation FD Disclosure (Jun 12, 2024)

Filed June 12, 2024For Securities:ELV

Summary

Elevance Health, Inc. filed an 8-K on June 12, 2024, primarily to reaffirm its financial guidance for the full year 2024. The company indicated that officers will be speaking with investors and intend to reaffirm the previously issued net income guidance. Specifically, Elevance expects full-year 2024 net income to be greater than $34.05 per diluted share. This includes an estimated $3.15 per diluted share attributed to net unfavorable items. Excluding these specific unfavorable items, Elevance Health continues to anticipate adjusted net income to be greater than $37.20 per diluted share. Investors should note that this guidance is based on information available as of the first quarter of 2024 earnings release and does not incorporate any further adjustments not previously disclosed. The filing also includes standard forward-looking statements and risk factors that investors should consider.

Key Highlights

  • 1Elevance Health reaffirms its full-year 2024 net income guidance.
  • 2The company expects full-year 2024 net income to be greater than $34.05 per diluted share.
  • 3Net unfavorable items are estimated to impact EPS by approximately $3.15.
  • 4Excluding these items, adjusted net income is projected to be greater than $37.20 per diluted share.
  • 5The guidance is based on information from the Q1 2024 earnings release.
  • 6No additional adjustment items beyond those reported in Q1 2024 are included in the reaffirmed guidance.
  • 7The filing serves as a Regulation FD disclosure for upcoming investor communications.

Frequently Asked Questions

The main purpose of this 8-K filing is to reaffirm Elevance Health's full-year 2024 financial guidance in anticipation of upcoming investor meetings, fulfilling Regulation FD disclosure requirements.

Elevance Health reaffirmed its guidance for full-year 2024 net income to be greater than $34.05 per diluted share. Excluding net unfavorable items of approximately $3.15 per diluted share, the company expects adjusted net income to be greater than $37.20 per diluted share.

No, the guidance reaffirms previously issued expectations and does not include any other adjustment items beyond those reported in the company's first quarter 2024 earnings release. Investors should refer to the Q1 earnings release for details on the identified unfavorable items.

The filing includes standard forward-looking statements and lists numerous risks and uncertainties, such as trends in healthcare costs and utilization, regulatory changes, cyber-attacks, economic conditions, competitive pressures, government program risks (Medicare/Medicaid), quality ratings, litigation, and potential impacts from mergers and acquisitions.